title: Escheriosome-mediated cytosolic delivery  of PLK1-specific siRNA: potential in  treatment  of liver cancer in BALB/c mice.
abstract: OBJECTIVE
  In the present study, the anticancer efficacy of a novel escheriosome-based formulation of PLK1-specific siRNA was evaluated against liver cancer in BALB/c mice.
  
  
  METHODS
  The escheriosome-based siRNA nanoparticles were prepared using lipids isolated from Escherichia coli. The escheriosomes were characterized for size, surface charge and stability. The anticancer potential of PLK1-specific siRNA formulation was ascertained on the basis of expression of pro-/anti-apoptotic factors and histopathological studies.
  
  
  RESULTS
  The escheriosome-entrapped siRNA was found to be released in surrounding milieu in a sustained manner. The nanoformulation was successful in modulating proapoptotic factors and eventually helped in better survival of the treated animals.
  
  
  CONCLUSIONS
  Our data demonstrate the efficacy of systemically administered siRNA in the treatment of experimental liver cancer. This novel therapeutic strategy may be applicable to a broad range of cancers in patients with the obstinate form of the disease.
authors.forename: Arun
authors.initials: A
authors.lastname: Chauhan
authors.forename: Swaleha
authors.initials: S
authors.lastname: Zubair
authors.forename: Ahmad
authors.initials: A
authors.lastname: Nadeem
authors.forename: Sajid Ali
authors.initials: SA
authors.lastname: Ansari
authors.forename: Mohammad Yunus
authors.initials: MY
authors.lastname: Ansari
authors.forename: Owais
authors.initials: O
authors.lastname: Mohammad
mesh_terms: D000818:Animals; D018797:Cell Cycle Proteins / Q000235:genetics*; D016503:Drug Delivery Systems; D004926:Escherichia coli / Q000737:chemistry*; D005260:Female; D015316:Genetic Therapy; D008055:Lipids / Q000737:chemistry* / Q000302:isolation & purification; D008099:Liver / Q000473:pathology; D008113:Liver Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D053758:Nanoparticles / Q000737:chemistry*; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*; D000097869:Polo-Like Kinase 1
chemical_list: D018797:Cell Cycle Proteins; D008055:Lipids; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D034741:RNA, Small Interfering; D000097869:Polo-Like Kinase 1